Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | heterochromatin protein 1 | 0.0073 | 0.2059 | 0.2059 |
Brugia malayi | Carboxylesterase family protein | 0.0214 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0177 | 0.792 | 0.792 |
Loa Loa (eye worm) | hypothetical protein | 0.0092 | 0.3143 | 0.3143 |
Onchocerca volvulus | Heterochromatin protein 1 homolog | 0.0044 | 0.0435 | 1 |
Schistosoma mansoni | chromobox protein | 0.0073 | 0.2059 | 0.2059 |
Trichomonas vaginalis | chromobox protein, putative | 0.0073 | 0.2059 | 1 |
Schistosoma mansoni | chromobox protein | 0.0073 | 0.2059 | 0.2059 |
Echinococcus granulosus | chromobox protein 1 | 0.0073 | 0.2059 | 0.2059 |
Loa Loa (eye worm) | carboxylesterase | 0.0214 | 1 | 1 |
Echinococcus multilocularis | chromobox protein 1 | 0.0073 | 0.2059 | 0.2059 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0214 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0177 | 0.792 | 0.792 |
Echinococcus granulosus | carboxylesterase 5A | 0.0214 | 1 | 1 |
Onchocerca volvulus | Heterochromatin protein 1 homolog | 0.0041 | 0.0261 | 0.5995 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0214 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0214 | 1 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0214 | 1 | 1 |
Mycobacterium tuberculosis | Carboxylesterase LipT | 0.0036 | 0 | 0.5 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0036 | 0 | 0.5 |
Echinococcus multilocularis | chromobox protein 1 | 0.0073 | 0.2059 | 0.2059 |
Brugia malayi | chromobox protein homolog 3 | 0.0041 | 0.0261 | 0.0261 |
Echinococcus multilocularis | geminin | 0.0177 | 0.792 | 0.792 |
Echinococcus granulosus | geminin | 0.0177 | 0.792 | 0.792 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0041 | 0.0261 | 0.1266 |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0041 | 0.0261 | 0.1266 |
Echinococcus multilocularis | acetylcholinesterase | 0.0214 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0214 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0092 | 0.3143 | 0.3143 |
Trichomonas vaginalis | chromobox protein, putative | 0.0044 | 0.0435 | 0.2112 |
Mycobacterium tuberculosis | POSSIBLE PARA-NITROBENZYL ESTERASE (FRAGMENT) | 0.0036 | 0 | 0.5 |
Schistosoma mansoni | eyes absent homolog | 0.0092 | 0.3143 | 0.3143 |
Echinococcus multilocularis | acetylcholinesterase | 0.0214 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0261 | 0.0261 |
Mycobacterium ulcerans | carboxylesterase, LipT | 0.0036 | 0 | 0.5 |
Trichomonas vaginalis | chromobox protein, putative | 0.0044 | 0.0435 | 0.2112 |
Echinococcus granulosus | acetylcholinesterase | 0.0214 | 1 | 1 |
Brugia malayi | Heterochromatin protein 1 | 0.0073 | 0.2059 | 0.2059 |
Brugia malayi | hypothetical protein | 0.0092 | 0.3143 | 0.3143 |
Echinococcus granulosus | chromobox protein 1 | 0.0073 | 0.2059 | 0.2059 |
Trichomonas vaginalis | chromobox protein, putative | 0.0073 | 0.2059 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | = 30 uM | Antiproliferative activity against human CEM cells after 3 days | ChEMBL. | 19281225 |
IC50 (ADMET) | = 42 uM | Antiproliferative activity against mouse L1210 cells after 2 days | ChEMBL. | 19281225 |
MCC (ADMET) | = 100 uM | Cytotoxicity against human HeLa cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days | ChEMBL. | 19281225 |
MCC (ADMET) | = 100 uM | Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days | ChEMBL. | 19281225 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.